http://hdl.handle.net/10401/293 Buscar el canal buscar http://www.bibliopsiquis.com/bibliopsiquis/simple-search http://hdl.handle.net/10401/1491 Título: A flexible-dose study of Paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with other oral antipsychotics.<br/><br/>Autor: Schreiner, A.; Hoeben, D.; Lahaye, M.; Tessier, C.; Peuskens, J.; Nardini, F.; Albrecht, W.; Jakovljevic, M.; Djukic-Dejanovic, S.<br/><br/>Resumen: ● Among patients transitioned to paliperidone ER for the main reason of lack of efficacy with their previous oral antipsychotic, 61% had an improvement in PANSS total scores of ≥ 20% from baseline to endpoint.● Among patients switching to paliperidone ER for main reasons other than lack of efficacy, PANSS total score at endpoint was not inferior to PANSS total score atbaseline. Even more, PANSS total score from baseline to endpoint improved significantly (P < 0.0001).● Clinically relevant and statistically significant improvements were observed for PANSS total, PANSS subscale, and Marder factor scores (P < 0.0001).● The percentage of patients in CGI-S categories mildly ill or less increased from 27% at baseline to 52% at endpoint.● The percentage of patients with PSP-defined mild functional impairment increased from 16% to 35% from baseline to endpoint.● AEs occurring in ≥ 5% of patients were insomnia (9.2%) and anxiety (7.1%).● ESRS scores decreased (i.e., improved) statistically significantly from 3.5 ± 5.8 to 2.1 ± 4.6 (P < 0.0001).● Mean body weight change from baseline to endpoint was 0.3 ± 4.8 kg.● Flexibly dosed paliperidone ER treatment over 6 months was safe, well tolerated, and associated with meaningful clinical response in patients previously unsuccessfullytreated with oral antipsychotics, supporting recent randomized controlled studies.<br/><br/>Descripción: Póster presentado en: 27th Collegium Internationale Neuro-Psychopharmacologicum (CINP) World Congress 2010. Hong Kong: 6-10 Junio de 2010. http://hdl.handle.net/10401/1490 Título: A flexible-dose study of Paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with Aripiprazole.<br/><br/>Autor: Schreiner, A.; Hoeben, D.; Lahaye, M.; Tessier, C.; Naber, D.; Peuskens, J.; Vauth, R.; Jasovic-Gasic, M.; Rancans, E.; Didi, R.<br/><br/>Resumen: *Among non-acute patients with schizophreniatransitioned to paliperidone ER for the main reason of lack of efficacy with previous aripiprazole treatment,more than 58% had an improvement in PANSS total scores of ≥ 20% from baseline to endpoint.*Among patients switching to paliperidone ER from aripiprazole for main reasons of lack of tolerability and reasons other than lack of efficacy, tolerability, or compliance, PANSS total scores at endpoint met prespecified non-inferiority criteria.*For all patients, PANSS total score from baseline to endpoint improved significantly (P < 0.0001).*Clinically relevant and statistically significant improvements occurred in PANSS total, subscale, and Marder factor scores (P < 0.05), with significant improvements in PANSS total scores noted from the first post-baseline assessment (4 weeks after initiating paliperidone ER).*The percentage of patients with severe or varying degrees of functional impairment decreased from 91% at baseline to 72% at endpoint.*Patient satisfaction, an important predictor for adherence to treatment, was good or very good in 18% of patients previously unsuccessfully treated witharipiprazole. Patient satisfaction after treatment with paliperidone ER was good or very good in 57% of patients.*TEAEs occurring in ≥ 5% of patients were anxiety (7.8%), insomnia (7.8%), somnolence (7.1%), weight increase (6.4%), and akathisia (5.0%).*ESRS scores decreased (i.e. improved) statistically significantly from 3.2 ± 4.5 to 2.3 ± 4.3 (P = 0.0004). This statistically significant, while numerically small,improvement may be clinically relevant as aripiprazole is generally considered to be well tolerated.*Mean body weight change from baseline to endpoint after switching to paliperidone ER was only 0.6 ± 4.7 kg.*Flexibly dosed paliperidone ER treatment over 6 months was safe, well tolerated, and associated with meaningful treatment response in patients previouslyunsuccessfully treated with aripiprazole.<br/><br/>Descripción: Póster presentado en: 27th Collegium Internationale Neuro-Psychopharmacologicum (CINP) World Congress 2010. Hong Kong: 6-10 Junio de 2010. http://hdl.handle.net/10401/1489 Título: Predictors for treatment response in patients with acute schizophrenia.<br/><br/>Autor: Schreiner, Andreas; Blanc, Michel; Bidzan, Leszek; Hoeben, Dagmar; Badescu, George Mihai; Schmauss, Max; Kotler, Moshe<br/><br/>Resumen: Paliperidone ER is formulated for once-daily, extended-release treatment using an innovative osmoticrelease technology that allows patients to achieve therapeutically effective dosing starting from the initial dose.– The formulation predicts early-onset efficacy with low peak-to-trough fluctuations over 24 hours, allowing for once-daily treatment– Paliperidone ER is approved for the treatment of schizophrenia, with efficacy and safety demonstrated in randomized controlled clinical trials● Demographic and baseline characteristics have been shown to predict treatment response in patients with schizophrenia or related disorders treated with oral risperidone or haloperidol.● Antipsychotic polypharmacy predicts in-patient treatment with high doses of antipsychotics.<br/><br/>Descripción: Póster presentado en: 27th Collegium Internationale Neuro-Psychopharmacologicum (CINP) World Congress 2010. Hong Kong: 6-10 Junio de 2010. http://hdl.handle.net/10401/1488 Título: A prospective randomized controlled trial of Paliperidone ER versus oral Olanzapine in patients with schizophrenia.<br/><br/>Autor: Schreiner, A.; Tessier, C.; Hoeben, D.; Korcsog, P.; Niehaus, D.; Aadamsoo, K.; Ucok, A.; Franco, M.; Theodoropoulou, P.<br/><br/>Resumen: ● Efficacy and overall safety and tolerability were similar with paliperidone ER and olanzapine, and significantimprovements in psychotic symptoms were observed with both treatments (P < 0.0001 versus baseline).● Insulin resistance, as measured by changes in TG:HDL ratio versus baseline, was significantly higher at endpoint with olanzapine compared with paliperidone ER.● Newly diagnosed impairment in TG and metabolic syndrome was more common with olanzapine than paliperidone ER (P < 0.05).● Endpoint increase in body weight was significantly higher with olanzapine than paliperidone ER (3.8 versus 1.2 kg,P = 0.0013).● Endpoint increase in waist circumference was significantly higher with olanzapine than paliperidone ER (3.4 versus0.70 cm, P < 0.0001).● This 6-month, randomized, comparative study confirms significant advantages in the metabolic profile of flexible doses of the newer atypical antipsychotic paliperidoneER compared with oral olanzapine. Olanzapine showed significantly more weight gain, lipid changes, insulin resistance, and new-onset metabolic syndrome, whereas efficacy of paliperidone ER was demonstrated to benon-inferior compared with oral olanzapine treatment.<br/><br/>Descripción: Póster presentado en: 27th Collegium Internationale Neuro-Psychopharmacologicum (CINP) World Congress 2010. Hong Kong: 6-10 Junio de 2010.